Zenas BioPharma Files 8-K on Financials
Ticker: ZBIO · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1953926
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
Zenas BioPharma dropped its 8-K, check the financials.
AI Summary
Zenas BioPharma, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 852 Winter Street, Suite 250, Waltham, MA.
Why It Matters
This 8-K filing provides investors with crucial updates on Zenas BioPharma's financial performance and condition, which can influence investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Zenas BioPharma, Inc. (company) — Registrant
- August 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 852 Winter Street, Suite 250 (address) — Principal executive offices
- Waltham, MA (location) — City and State of principal executive offices
- 02451 (zip_code) — Zip code of principal executive offices
- 857-271-2954 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Zenas BioPharma, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 12, 2025.
In which state is Zenas BioPharma, Inc. incorporated?
Zenas BioPharma, Inc. is incorporated in Delaware.
What is the address of Zenas BioPharma, Inc.'s principal executive offices?
The address of Zenas BioPharma, Inc.'s principal executive offices is 852 Winter Street, Suite 250, Waltham, MA 02451.
What is the telephone number for Zenas BioPharma, Inc.?
The telephone number for Zenas BioPharma, Inc. is (857) 271-2954.
Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-08-12 07:13:47
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ZBIO The Nasdaq Global Se
Filing Documents
- tm2523154d1_8k.htm (8-K) — 28KB
- tm2523154d1_ex99-1.htm (EX-99.1) — 40KB
- tm2523154d1_ex99-1img01.jpg (GRAPHIC) — 3KB
- 0001104659-25-076464.txt ( ) — 244KB
- zbio-20250812.xsd (EX-101.SCH) — 3KB
- zbio-20250812_lab.xml (EX-101.LAB) — 33KB
- zbio-20250812_pre.xml (EX-101.PRE) — 22KB
- tm2523154d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On August 12, 2025, Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on August 12 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENAS BIOPHARMA, INC. By: /s/ Jennifer Fox Name: Jennifer Fox Title: Chief Business Officer and Chief Financial Officer Date: August 12, 2025